期刊文献+

HLA-DR13基因与丙型肝炎病毒感染外周血单个核细胞的关系 被引量:2

Association between HLA-DR13 and Peripheral Blood Mononuclear Cell(PBMC) in HCV Infection
下载PDF
导出
摘要 目的:探讨人类白细胞抗原(HLA)中的DR13基因对慢性丙型肝炎患者中丙型肝炎病毒(HCV)感染外周血单个核细胞(PBMC)的影响。方法:选择75例已经确诊为慢性丙型肝炎患者,采用PCR-SSP方法检测HLA-DR13基因,用密度梯度离心法分离收集PBMC,按是否携带HLA-DR13基因分为两组,观察HLA-DR13基因与HCV感染PBMC的关系。结果:本组携带HLA-DR13基因者17例,PBMC阳性4例(23.5%),未携带HLA-DR13基因者58例,PBMC阳性36例(62.1%),采用四格表χ2检验,两组差异有统计学意义(χ2=7.85,P<0.01)。结论:HLA-DR13基因可能与HCV感染PBMC有关。 Objective:To study the effect of HLA-DR13 on PBMC in HCV infection. Methods:Genomic DNA was analyzed by pol- ymerase chain reaction/sequence specific primer(PCR-SSP) technique,and the PCR products were purified and sequenced. RTPCR was applied to detect HCV RNA in PBMC. Results:Of 75 chronic hepatitis C patients, HLA-DR13 was detected in 17 patients in which 4 (23.5%) patients with PBMC-HCV RNA positive. HLA-DR13 was negative in 58 patients in which 36 (62.1% ) patients with PBMC-HCV RNA positive, there was significant difference( X^2 = 7.85, P 〈 0.01 ). Conclusion: HLA-DR13 maybe have some influence on PBMC in HCV infection.
作者 石国梁
机构地区 安阳地区医院
出处 《临床误诊误治》 2007年第5期12-13,共2页 Clinical Misdiagnosis & Mistherapy
关键词 肝炎 丙型 慢性 HLA抗原 丙型肝炎病毒 外周血单个核细胞 Hepatitis C, chronic Human leukocyte antigen Hepatitis C virus Peripheral blood mononuclear cell
  • 相关文献

参考文献16

  • 1丙型肝炎防治指南[J].实用肝脏病杂志,2004,7(3). 被引量:38
  • 2刘文恩,谭德明,范学工,张铮,甘晓明,欧阳颗,谢玉桃.HCV感染者血清及外周血单个核细胞HCV RNA检测及其意义[J].中国现代医学杂志,2001,11(2):31-32. 被引量:4
  • 3Sansonno D,Iacobelli A R,Cornacchiulo V,et al.Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients[J].Clin Exp Immunol,1996,103(3):414-421.
  • 4Zignego A L,Macchia D,Monti M,et al.Infection of peripheral mononuclear blood cells by hepatitis C Virus[J].Hepatol,1992,15(3):382-386.
  • 5Cribier B,Schmitt C,Bingen A,et al.In vitro infection of peripheral blood mononuclear cells by hepatitis C virus[J].Gen Virol,1995,76 (10):2485-2491.
  • 6Saleh M G,Tibbs C J,Koskinas J,et al.Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy[J].Hepatology,1994,20(6):1399-1404.
  • 7贺永文,刘薇,曾令兰,熊开均,罗端德.干扰素联合病毒唑对肝炎患者正、负链丙型肝炎病毒RNA的影响[J].中华内科杂志,1996,35(1):32-35. 被引量:13
  • 8Wang J T,Sheu J C,Lin J T,et al.Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells[J].J Infect Dis,1992,166(5):1167-1169.
  • 9Thursz M R,Kwiatkowski D,Allspp C E,et al.Association between an MHC class Ⅱ allele and clearance of hepatitis B virus in the Gambia[J].N Engl Med,1995,332(16):1065-1069.
  • 10Karayiannis P,Alexopoulou A,Hadziyannis S,et al.Fulminant hepatitis associated with hepatitis B virus e antigen-negative infection:importance of host factors.[J].Hepatology,1995,22(6):1628-1634.

二级参考文献19

  • 1贺永文,刘薇,曾令兰,熊开均,罗端德.干扰素联合病毒唑对肝炎患者正、负链丙型肝炎病毒RNA的影响[J].中华内科杂志,1996,35(1):32-35. 被引量:13
  • 2马志敏,冯懿正,陈智.肝癌和癌旁组织中HCV—RNA及其负链的研究[J].中国现代医学杂志,1997,7(5):1-3. 被引量:2
  • 3李威 乔光彦 等.丙型肝炎患者外周CD^+4,cd^+8,NK细胞分析[J].中华微生物和免疫学杂志,1992,12:363-363.
  • 4[1]Alberit A, Benvegnu L. Management of hepatitis C. J Hepatol,2003,38(suppl 1): S1014 ~ S118
  • 5[2]Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut,2001,49(Suppl Ⅰ) :S1 ~ S12
  • 6[3]Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribvirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut, 2002,51: 864 ~ 869
  • 7[4]Chander G, Sulkowski MS, Jenckes MW. et al. Treatment of chronic hepatitis C: a systemic review. Hepatology, 2002,36 (5 suppl 1 ):S135 ~ S144
  • 8[5]DiCiommo V, Russo P, Rave L, et al. Interferon alpha in the treatment of chronic hepatits C in children: a meta-analysis. J Viral Hepat,2003, 10:210 ~ 214
  • 9[6]Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther,2003,18:1071 ~ 1081
  • 10[7]Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ, 2001,323:1151 ~ 1155

共引文献70

同被引文献50

  • 1焦健,王江滨.中国东北丙型肝炎病毒感染基因特征及人群易感性分析[J].临床肝胆病杂志,2005,21(2):68-70. 被引量:5
  • 2Stéphane Chevaliez,Jean-Michel Pawlotsky.Hepatitis C virus: Virology, diagnosis and management ofantiviral therapy[J].World Journal of Gastroenterology,2007,13(17):2461-2466. 被引量:17
  • 3Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol, 2006, 118 : 1-10.
  • 4Lavanchy D. The global burdett-of hepatitis C. Liver Int, 2009, 29 : 74-81.
  • 5Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease . J Exp Med, 2005, 1 : 1025-1029.
  • 6Khakoo SI, Thio CL, Martin MP, et al . HLA and NK cell in- hibitory receptor genes in resolving hepatitis C virus infection. Science, 2004, 305:872-874.
  • 7Ahlenstiel G, Martin MP, Gao X, et al. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natu- ral killer cell responses. J Clin Invest, 2008, 118: 1017- 1026.
  • 8Carriugton M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol, 2006, 298: 225-257.
  • 9Abi-Rached L, Parham P. Natural selection drives recurrent for- mation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. Exp Med, 2005, 201 : 131- 132.
  • 10Shiina T, Hosomichi K, Inoko H, et al. The HLA genomie loci map: expression, interaction, diversity and disease. J Hum Genet, 2009, 54 : 15-39.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部